lyophilised powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-15. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Modern units use a magnetic door gasket that holds the door sealed but allows it to be pushed open from the inside. This gasket was invented, developed and manufactured by Max Baermann (1903–1984) of Bergisch Gladbach/Germany. Regarding total life-cycle costs, many governments offer incentives to encourage recycling of old refrigerators. One example is the Phoenix refrigerator program launched in Australia. This government incentive picked up old refrigerators, paying their owners for "donating" the refrigerator. The refrigerator was then refurbished, with new door seals, a thorough cleaning, and the removal of items such as the cover that is strapped to the back of many older units. The resulting refrigerators, now over 10% more efficient, were then given to low-income families. The United States also has a program for collecting and replacing older, less-efficient refrigerators and other white goods. These programs seek to replace large appliances that are old and inefficient or faulty by newer, more energy-efficient appliances, to reduce the cost imposed on lower-income families, and reduce pollution caused by the older appliances.
== Production == On September 2, 2021, BET+ renewed the series for a second season which premiered on August 11, 2022. On July 6, 2022, BET+ renewed the series for a third season, which premiered on February 23, 2023. On May 30, 2023, BET+ renewed the series for a fourth season, which premiered on May 23, 2024. On October 31, 2024, BET+ renewed the series for a fifth season, which premiered on January 7, 2026. On March 26, 2026, the series was renewed for a sixth season, which will move to Paramount+ after the shutdown of BET+.
== History == ARUP was founded by John Matsen and Carl Kjeldsberg, based on Lloyd Martin's vision of an independent, not-for-profit laboratory owned by the Department of Pathology. ARUP's facilities operate with a high degree of automation. Their 65 laboratories include sorters, automated thawing and mixing, and house a two-story automated lab specimen freezer. The freezer can store 2.3 million specimens and retrieve a specimen in 2.5 minutes. In 2003, ARUP partnered with the Utah Department of Health to create a pilot program for expanding newborn screening in Utah to include an additional 30 metabolic markers. A year later, this program became the standard for the mandatory screening of all newborns in the state of Utah.
Oliceridine, sold under the brand name Olinvyk, is an opioid medication that is used for the treatment of moderate to severe acute pain in adults. It is given by intravenous (IV) injection. The most common side effects include nausea, vomiting, dizziness, headache, constipation, itchy skin and low oxygen levels in blood. It was approved for medical use in the United States in August 2020.
Sources: en.wikipedia.org
July 22 – After Sherman Packard strips Lynne Ober of her committee leadership position, Lynne and her husband Russell resign from the New Hampshire House of Representatives in protest. July 23 – Cleveland's Major League Baseball team announces that they will change their name from the Indians to the Guardians, resolving a decades-long controversy. July 23–August 8 – The United States compete at the Summer Olympics in Tokyo, Japan and win 39 gold, 41 silver, and 33 bronze medals. July 25 – 2020 Summer Olympics: American fencer Lee Kiefer wins a gold medal at the women's foil event for fencing, making her the first American woman to do so. Additionally, Anastasija Zolotic becomes the first American woman to win a gold medal in taekwondo. July 27 A runoff election is held in Texas to fill a vacancy in its 6th congressional district due to the death of Ron Wright on February 7. Republican Jake Ellzey wins with 20,837 of the 39,116 votes cast (53.27%). Whatcom County, Washington becomes the first state county to ban new fossil fuel infrastructure. The new law also places restrictions on existing fossil fuel facilities, such as a requirement that any greenhouse gases emitted from expansion be offset. July 28 The Senate votes 67–32 to advance the Infrastructure Investment and Jobs Act, a bipartisan $1.2 trillion infrastructure bill. Swimming at the 2020 Summer Olympics: Florida swimmer Bobby Finke becomes the first American to win a gold medal at the 800 metre freestyle event at the Olympics.
High performance affinity chromatography (HPAC) works by passing a sample solution through a column packed with a stationary phase that contains an immobilized biologically active ligand. The ligand is in fact a substrate that has a specific binding affinity for the target molecule in the sample solution. The target molecule binds to the ligand, while the other molecules in the sample solution pass through the column, having little or no retention. The target molecule is then eluted from the column using a suitable elution buffer. This chromatographic process relies on the capability of the bonded active substances to form stable, specific, and reversible complexes thanks to their biological recognition of certain specific sample components. The formation of these complexes involves the participation of common molecular forces such as the Van der Waals interaction, electrostatic interaction, dipole-dipole interaction, hydrophobic interaction, and the hydrogen bond. An efficient, specific bond is formed by a simultaneous and concerted action of several of these forces in the complementary binding sites.
Bacterial metabolic traits play important roles in maintaining ecological processes and supporting human activities. For example, diazotrophs have the ability to fix nitrogen gas using the enzyme nitrogenase. This trait, which can be found in bacteria of most metabolic types listed above, leads to the ecologically important processes of denitrification, sulfate reduction, and acetogenesis, respectively. Bacterial metabolic processes are important drivers in biological responses to pollution; for example, sulfate-reducing bacteria are largely responsible for the production of the highly toxic forms of mercury (methyl- and dimethylmercury) in the environment. Nonrespiratory anaerobes use fermentation to generate energy and reducing power, secreting metabolic by-products (such as ethanol in brewing) as waste. Facultative anaerobes can switch between fermentation and different terminal electron acceptors depending on the environmental conditions in which they find themselves.
α-Haloesters are generally thought of as highly reactive and consequently toxic intermediates in organic synthesis. Nevertheless, mammals, including humans, cats, and rats, appear to biosynthesise traces of an α-bromoester, 2-octyl 4-bromo-3-oxobutanoate, which is found in their cerebrospinal fluid and appears to play a yet unclarified role in inducing REM sleep. Neutrophil myeloperoxidase can use H2O2 and Br− to brominate deoxycytidine, which could result in DNA mutations. Marine organisms are the main source of organobromine compounds, and it is in these organisms that bromine is more firmly shown to be essential. More than 1600 such organobromine compounds were identified by 1999. The most abundant is methyl bromide (CH3Br), of which an estimated 56,000 tonnes is produced by marine algae each year. The essential oil of the Hawaiian alga Asparagopsis taxiformis consists of 80% bromoform. Most of such organobromine compounds in the sea are made by the action of a unique algal enzyme, vanadium bromoperoxidase. The bromide anion is not very toxic: a normal daily intake is 2 to 8 milligrams. However, high levels of bromide chronically impair the membrane of neurons, which progressively impairs neuronal transmission, leading to toxicity, known as bromism. Bromide has an elimination half-life of 9 to 12 days, which can lead to excessive accumulation. Doses of 0.5 to 1 gram per day of bromide can lead to bromism. Historically, the therapeutic dose of bromide is about 3 to 5 grams of bromide, thus explaining why chronic toxicity (bromism) was once so common.
== Problems and current disadvantages == A primary issue accompanying BsAb development since the early stages has been achieving a high ratio of correctly paired bispecific antibodies. Early attempts to produce BsAbs resulted in large amounts of homodimers and other mispaired fragments. Novel pairing technologies have been developed to increase the heterodimerization rate, leading to higher yields and reduced production costs. Furthermore, IgG-like antibodies can be immunogenic, which means the Fc region could cause detrimental downstream immune responses caused by cells that are activated by Fc receptors. The therapeutic use of BsAbs as a whole is still largely in development, with many clinical trials currently ongoing that are determining the efficacy and safety of BsAbs for treatment. One major area of concern is the feasibility of administration and management of side effects, where the potential for therapeutic success must be weighed against possible risks. The occurrence of side effects primarily depends on the specific antibody, its target, and patient-specific factors. These factors have to be individually examined for each patient in order to evaluate the feasibility of a bispecific antibody treatment, and to assess the risk of infusion-related, immune-related, organ-specific, and hematologic side effects.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.